Lung cancer remains a leading cause of cancer death globally, with a significant rise in cases among non-smokers attributed ...

Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) ...

A recent study published in The Lancet Respiratory Medicine revealed an increase in lung cancer cases among non-smokers, ...

The number of lung cancer diagnoses amongst people who have never smoked is increasing globally, according to the World ...

Studies have shown that specific gene variations make women more susceptible to lung cancer, even without smoking.

Estimated geographical and temporal distribution of lung-cancer incidence varied across the four main subtypes worldwide. Our ...

Media Release Marking Immutep's transition to a Phase III biotech, the Company's pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approvalMature da ...

New Delhi: Drug major Glenmark Pharmaceutical has got the go-ahead from the Subject Expert Committee (SEC) functional under ...

and doublet chemotherapy as first-line treatment for patients with advanced or metastatic non-squamous non-small cell lung cancer (1L NSCLC). Mature data from patients with a minimum follow-up of 22 ...

Transarterial infusion chemotherapy and embolization (TAICE) as a pre-operative therapy for patients with locally advanced gastric cancer (LAGC): A prospective, single-arm, pilot study.

Lung cancer remains the leading cause of cancer-related deaths globally, with cigarette smoking as its primary driver. Chemical carcinogens like polycyclic aromatic hydrocarbons (PAHs) in tobacco ...

Symptoms and treatment options depend on the stage of your lung cancer along with what type of NSCLC you're diagnosed with. There are three primary types: adenocarcinoma, squamous cell carcinoma, and ...